BACKGROUND: In vitro evidence has suggested that increasing levels of norepinephrine (NE) can accelerate HIV replication; however, the importance in a clinical setting has not been tested. PURPOSE: The purpose of this study was to determine if perceived stress as well as the stress hormones NE and cortisol would predict the response to starting a new protease inhibitor (PI) prospectively. METHOD: Perceived stress, urinary cortisol and norepinephrine, CD4 and viral load (VL) were measured in people with HIV before starting a new PI and six months later (an average of three months after starting the new PI) in order to determine CD4 and VL response to the PI. RESULTS: Higher perceived stress significantly predicted lower effectiveness of the new PI in increasing CD4 and decreasing VL controlling for age, duration of new PI, baseline CD4/VL, sexually transmitted diseases (STDs), and gender/ethnic risk groups. Higher norepinephrine, but not cortisol, predicted worse VL response to PIs and, in fact, mediated the relationship between perceived stress and change in VL. CONCLUSION: Perceived stress and high norepinephrine levels are prospectively associated with a poorer response to starting a new PI. Assessing stress and norepinephrine levels in patients starting on antiretroviral medications might be clinically useful.
BACKGROUND: In vitro evidence has suggested that increasing levels of norepinephrine (NE) can accelerate HIV replication; however, the importance in a clinical setting has not been tested. PURPOSE: The purpose of this study was to determine if perceived stress as well as the stress hormones NE and cortisol would predict the response to starting a new protease inhibitor (PI) prospectively. METHOD: Perceived stress, urinary cortisol and norepinephrine, CD4 and viral load (VL) were measured in people with HIV before starting a new PI and six months later (an average of three months after starting the new PI) in order to determine CD4 and VL response to the PI. RESULTS: Higher perceived stress significantly predicted lower effectiveness of the new PI in increasing CD4 and decreasing VL controlling for age, duration of new PI, baseline CD4/VL, sexually transmitted diseases (STDs), and gender/ethnic risk groups. Higher norepinephrine, but not cortisol, predicted worse VL response to PIs and, in fact, mediated the relationship between perceived stress and change in VL. CONCLUSION: Perceived stress and high norepinephrine levels are prospectively associated with a poorer response to starting a new PI. Assessing stress and norepinephrine levels in patients starting on antiretroviral medications might be clinically useful.
Authors: S W Cole; B D Naliboff; M E Kemeny; M P Griswold; J L Fahey; J A Zack Journal: Proc Natl Acad Sci U S A Date: 2001-10-23 Impact factor: 11.205
Authors: Michael P Arnold; Michele Andrasik; Stewart Landers; Shelly Karuna; Matthew J Mimiaga; Steven Wakefield; Kenneth Mayer; Susan Buchbinder; Beryl A Koblin Journal: Am J Public Health Date: 2014-06-12 Impact factor: 9.308
Authors: Gail Ironson; Rick Stuetzle; Dale Ironson; Elizabeth Balbin; Heidemarie Kremer; Annie George; Neil Schneiderman; Mary Ann Fletcher Journal: J Behav Med Date: 2011-02-22
Authors: Roger C McIntosh; Gail Ironson; Michael Antoni; Betty Lai; Mahendra Kumar; Mary Ann Fletcher; Neil Schneiderman Journal: Int J Behav Med Date: 2017-04
Authors: Julia S Seay; Roger McIntosh; Erin M Fekete; Mary Ann Fletcher; Mahendra Kumar; Neil Schneiderman; Michael H Antoni Journal: Psychoneuroendocrinology Date: 2013-07-10 Impact factor: 4.905